A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer
出版年份 2018 全文链接
标题
A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer
作者
关键词
mTOR, Prostate cancer, MLN0128
出版物
INVESTIGATIONAL NEW DRUGS
Volume 36, Issue 3, Pages 458-467
出版商
Springer Nature
发表日期
2018-03-06
DOI
10.1007/s10637-018-0578-9
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer
- (2017) Alexander W Wyatt et al. JNCI-Journal of the National Cancer Institute
- Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer
- (2017) Alexander W Wyatt et al. JNCI-Journal of the National Cancer Institute
- TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia
- (2016) Irene M. Ghobrial et al. AMERICAN JOURNAL OF HEMATOLOGY
- Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
- (2016) Vanessa S. Rodrik-Outmezguine et al. NATURE
- Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications
- (2015) Dana E. Rathkopf et al. CANCER
- Feedback Suppression of PI3Kα Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3Kβ
- (2015) Sarit Schwartz et al. CANCER CELL
- Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
- (2015) Donavan T. Cheng et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Cell type–specific abundance of 4EBP1 primes prostate cancer sensitivity or resistance to PI3K pathway inhibitors
- (2015) Andrew C. Hsieh et al. Science Signaling
- YB-1 and MTA1 protein levels and not DNA or mRNA alterations predict for prostate cancer recurrence
- (2015) Christine Moore Sheridan et al. Oncotarget
- Cell type–specific abundance of 4EBP1 primes prostate cancer sensitivity or resistance to PI3K pathway inhibitors
- (2015) Andrew C. Hsieh et al. Science Signaling
- PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance
- (2014) AndrewC Hsieh et al. ASIAN JOURNAL OF ANDROLOGY
- Abstract C252: A phase 1, dose-escalation study of MLN0128, an investigational oral mammalian target of rapamycin complex 1/2 (mTORC1/2) catalytic inhibitor, in patients (pts) with advanced non-hematologic malignancies.
- (2014) J. R. Infante et al. MOLECULAR CANCER THERAPEUTICS
- Phase 2 Trial of Single-agent Everolimus in Chemotherapy-naive Patients with Castration-resistant Prostate Cancer (SAKK 08/08)
- (2013) Arnoud J. Templeton et al. EUROPEAN UROLOGY
- mTOR kinase structure, mechanism and regulation
- (2013) Haijuan Yang et al. NATURE
- The translational landscape of mTOR signalling steers cancer initiation and metastasis
- (2012) Andrew C. Hsieh et al. NATURE
- Oncogenic AKTivation of translation as a therapeutic target
- (2011) A C Hsieh et al. BRITISH JOURNAL OF CANCER
- Cell Autonomous Role of PTEN in Regulating Castration-Resistant Prostate Cancer Growth
- (2011) David J. Mulholland et al. CANCER CELL
- Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
- (2011) Brett S. Carver et al. CANCER CELL
- Genetic Dissection of the Oncogenic mTOR Pathway Reveals Druggable Addiction to Translational Control via 4EBP-eIF4E
- (2010) Andrew C. Hsieh et al. CANCER CELL
- Integrative Genomic Profiling of Human Prostate Cancer
- (2010) Barry S. Taylor et al. CANCER CELL
- A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer
- (2010) A. J. Armstrong et al. CLINICAL CANCER RESEARCH
- An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
- (2009) Carson C. Thoreen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Differential Requirement of mTOR in Postmitotic Tissues and Tumorigenesis
- (2009) C. Nardella et al. Science Signaling
- Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
- (2009) Morris E Feldman et al. PLOS BIOLOGY
- Pilot Study of Rapamycin in Patients with Hormone-Refractory Prostate Cancer
- (2008) Robert J. Amato et al. Clinical Genitourinary Cancer
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
- (2008) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation
- (2008) A. Y. Choo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started